<head>
    <!-- Stylesheet -->
    <link rel="stylesheet" href="css/efficacy.css">
</head>
<!-- Main -->
<main>
    <div class="tabs">
        <a href="" ui-sref="ORR" class="tab tab--active">ORR</a>
        <a href="" ui-sref="TUMOR-VOLUME-ASSESSMENT" class="tab">TUMOR VOLUME ASSESSMENT</a>
        <a href="" ui-sref="DOR" class="tab">DoR</a>
    </div>

    <h2 class="primary">BELEODAQ Exceeded the Target 20% ORR Considered Clinically Meaningful for the Study<sup>1,2,*</sup></h2>
    <div class="response-rate">
        <img src="assets/svg/efficacy/orr.svg" alt="Response Rate Data" />
        <h4 class="img-label light">An additional 15.0% had stable disease (n = 18)<sup>1,2</sup></h4>
        <h3 class="dark">Efficacy was observed in the 2 most common PTCL subtypes<sup>1,2</sup></h3>
        <img src="assets/svg/efficacy/orr2.svg" alt="ORR" />
    </div>

    <p class="light"><sup>*</sup>The primary study endpoint of ORR was based on an independent review, where a 20% ORR was considered clinically meaningful.<sup>2,†</sup> Sample size was based on a 2-stage optimal design, with a hypothesized ORR of the alternate hypothesis (p1 = 20%) for BELEODAQ and a minimal or uninteresting ORR of null hypothesis (p0 = 9%).<sup>2,§</sup> No meaningful difference in response rate was observed between patients ≥75 years and those &lt; 75 years.<sup>1</sup></p>
    <p class="light">AITL, angioimmunoblastic T-cell lymphoma; CR, complete response; ORR, overall response rate; PR, partial response; PTCL, peripheral T-cell lymphoma; PTCL-NOS, PTCL not otherwise speciﬁed.</p>
    <div class="button-group">
        <a href="" ui-sref="INCLUSION-CRITERIA" class="button secondary"><i class="fas fa-chevron-left"></i>Belief Trial</a>
        <a href="" ui-sref="SAFETY" class="button">Safety & Tolerability <i class="fas fa-chevron-right"></i></a>
    </div>
</main>